---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-26-000189"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2026-10-13T12:12:35+00:00"
generated_at: "2026-10-13T12:15:07.774750+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "medium"
source: SEC EDGAR
---

# J&J Q3 sales $25.4B, up 5.9%; GAAP EPS $0.09 (-95.8%) on $5.78B other expense; adj EPS $2.59 (-7.5%)

## Summary
- Q3 worldwide sales $25,399M vs $23,993M, +5.9% (operations +6.0%); U.S. +9.1% to $14,959M, international +1.5% to $10,440M.
- Innovative Medicine sales $16,757M, +7.7%; MedTech $8,642M, +2.5%, with MedTech international up just 0.1%.
- GAAP net earnings fell 95.9% to $210M and diluted EPS 95.8% to $0.09, driven by $5,780M of other (income) expense, net vs $(478)M income a year ago.
- Adjusted net earnings $6,339M (-6.8%) and adjusted diluted EPS $2.59 vs $2.80 (-7.5%); adjusted effective tax rate 17.4% vs 19.4%.
- R&D expense rose 26.7% to $4,652M and IPR&D impairments were $339M; nine-month worldwide sales $74,771M, +7.4%.

## SEC filing metadata
- accession: 0000200406-26-000189
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2026-10-13T12:12:35+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/0000200406-26-000189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040626000189/jnj-20261013.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-26-000189
- JSON: https://secwatch.observer/filing/0000200406-26-000189.json
- Plain text: https://secwatch.observer/filing/0000200406-26-000189.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.